Clinical Trials
47 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
SUNRAY-01
Eli Lilly and Company
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
LADOGA
AstraZeneca
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
LIBRETTO-001
Eli Lilly and Company
REVIVE
AstraZeneca
AcceleRET-Lung
Hoffmann-La Roche
LOTOS
AstraZeneca
VALOR
VA Office of Research and Development
LIBRETTO-121
Eli Lilly and Company
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
HYDRA
Leiden University Medical Center
TELESCOPE-H
Rutgers, The State University of New Jersey
FIRSTLUNG
Delfi Diagnostics Inc.
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
ARROW
Hoffmann-La Roche
Early Intervention Strategies for Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
ILST
The University of Queensland
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University
ALpha-T
Hoffmann-La Roche
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Jiangsu HengRui Medicine Co., Ltd.
A Phase I Study of iPS Cell Generation From Patients With COPD
Mayo Clinic
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)
Lifesemantics Corp.
ENCORE110
Syndax Pharmaceuticals
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
EPIC
University of Turin, Italy
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
HER3-Lung
Daiichi Sankyo
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Randomized Study of Hormonal Regulation of Infantile Hemangioma
FDA Office of Orphan Products Development
Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning
University of Luebeck